Rezdiffra Pregnancy and Lactation Registry (NCT07541469)
A Phase 4, Decentralized Observational Registry to Evaluate the Safety in Women With NASH and Their Infants Exposed to REZDIFFRA™ (Resmetirom) During Pregnancy and/or Lactation
🩺 Plain-English Summary (8th-Grade Level)
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
Who can join: Review the eligibility criteria below.
Location: Madrigal Pharmaceuticals — West Conshohocken, Pennsylvania
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Madrigal Pharmaceuticals — West Conshohocken, Pennsylvania
📞 Contact the Study Coordinator
Phone: (800) 905-0324
Email: MHGSafety@iconplc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in MASH - Metabolic Dysfunction-Associated Steatohepatitis
Explore by condition: All MASH - Metabolic Dysfunction-Associated Steatohepatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.